NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Trevena, Inc. (NASDAQ:TRVN), Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Endocyte, Inc. (NASDAQ:ECYT), FireEye, Inc. (NASDAQ:FEYE), CSRA Inc. (NYSE:CSRA), and Orchid Island Capital, Inc. (NYSE:ORC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
TRVN DOWNLOAD: http://Fundamental-Markets.com/register/?so=TRVN
FPRX DOWNLOAD: http://Fundamental-Markets.com/register/?so=FPRX
ECYT DOWNLOAD: http://Fundamental-Markets.com/register/?so=ECYT
FEYE DOWNLOAD: http://Fundamental-Markets.com/register/?so=FEYE
CSRA DOWNLOAD: http://Fundamental-Markets.com/register/?so=CSRA
ORC DOWNLOAD: http://Fundamental-Markets.com/register/?so=ORC
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Trevena, Inc. (NASDAQ:TRVN), Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Endocyte, Inc. (NASDAQ:ECYT), FireEye, Inc. (NASDAQ:FEYE), CSRA Inc. (NYSE:CSRA), and Orchid Island Capital, Inc. (NYSE:ORC) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 13th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
TREVENA, INC. (TRVN) REPORT OVERVIEW
Trevena's Recent Financial Performance
For the twelve months ended December 31st, 2016 vs December 31st, 2015, Trevena reported revenue of $3.75MM vs $6.25MM (down 40.00%) and basic earnings per share -$1.97 vs -$1.15. Trevena is expected to report earnings on March 14th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.67. The estimated EPS forecast for the next fiscal year is -$0.97 and is expected to report on March 14th, 2018.
To read the full Trevena, Inc. (TRVN) report, download it here: http://Fundamental-Markets.com/register/?so=TRVN
-----------------------------------------
FIVE PRIME THERAPEUTICS, INC. (FPRX) REPORT OVERVIEW
Five Prime Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Five Prime Therapeutics reported revenue of $8.33MM vs $6.68MM (up 24.75%) and basic earnings per share -$1.54 vs -$0.72. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Five Prime Therapeutics reported revenue of $30.69MM vs $379.80MM (down 91.92%) and basic earnings per share -$2.44 vs $9.73. Five Prime Therapeutics is expected to report earnings on February 27th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.73. The estimated EPS forecast for the next fiscal year is -$5.00 and is expected to report on February 22nd, 2018.
To read the full Five Prime Therapeutics, Inc. (FPRX) report, download it here: http://Fundamental-Markets.com/register/?so=FPRX
-----------------------------------------
ENDOCYTE, INC. (ECYT) REPORT OVERVIEW
Endocyte's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Endocyte reported revenue of $0.03MM vs $0.03MM (unchanged) and basic earnings per share -$0.55 vs -$0.21. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Endocyte reported revenue of $0.07MM vs $0.07MM (unchanged) and basic earnings per share -$1.04 vs -$0.98. Endocyte is expected to report earnings on March 9th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.26. The estimated EPS forecast for the next fiscal year is -$0.91 and is expected to report on March 9th, 2018.
To read the full Endocyte, Inc. (ECYT) report, download it here: http://Fundamental-Markets.com/register/?so=ECYT
-----------------------------------------
FIREEYE, INC. (FEYE) REPORT OVERVIEW
FireEye's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, FireEye reported revenue of $189.60MM vs $186.41MM (up 1.71%) and basic earnings per share -$0.41 vs -$0.75. For the twelve months ended December 31st, 2016 vs December 31st, 2015, FireEye reported revenue of $714.11MM vs $622.97MM (up 14.63%) and basic earnings per share -$2.94 vs -$3.50. FireEye is expected to report earnings on May 1st, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.34. The estimated EPS forecast for the next fiscal year is -$0.65 and is expected to report on February 14th, 2019.
To read the full FireEye, Inc. (FEYE) report, download it here: http://Fundamental-Markets.com/register/?so=FEYE
-----------------------------------------
CSRA INC. (CSRA) REPORT OVERVIEW
CSRA's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, CSRA reported revenue of $1,309.00MM vs $1,222.00MM (up 7.12%) and basic earnings per share $1.15 vs $0.77 (up 49.35%). For the twelve months ended March 31st, 2017 vs March 31st, 2016, CSRA reported revenue of $4,993.00MM vs $4,250.00MM (up 17.48%) and basic earnings per share $1.86 vs $0.54 (up 244.44%). CSRA is expected to report earnings on May 23rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.49. The estimated EPS forecast for the next fiscal year is $2.26 and is expected to report on May 23rd, 2018.
To read the full CSRA Inc. (CSRA) report, download it here: http://Fundamental-Markets.com/register/?so=CSRA
-----------------------------------------
ORCHID ISLAND CAPITAL, INC. (ORC) REPORT OVERVIEW
Orchid Island Capital's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Orchid Island Capital reported revenue of $38.97MM vs $22.36MM (up 74.32%) and basic earnings per share $0.33 vs $0.85 (down 61.18%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Orchid Island Capital reported revenue of $87.13MM vs $68.81MM (up 26.62%) and basic earnings per share $0.08 vs $0.05 (up 60.00%). Orchid Island Capital is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.07. The estimated EPS forecast for the next fiscal year is $1.50 and is expected to report on February 14th, 2019.
To read the full Orchid Island Capital, Inc. (ORC) report, download it here: http://Fundamental-Markets.com/register/?so=ORC
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.